Quick Facts

• Management of Certain Tumors: Indicated for advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST).
• Cancer Treatment: Used to manage progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs).
• Adjuvant Therapy: Approved as an adjuvant treatment for adult patients at high risk of recurrent RCC following surgery.

---

Sinton is a prescription medication approved for specific therapeutic domains in oncology. The compound is indicated for the management of gastrointestinal stromal tumors (GIST) when the condition has progressed or when patients experience intolerance to a prior standard treatment.

Additionally, Sinton is used to address advanced renal cell carcinoma (RCC). Its therapeutic use also extends to certain adult patients who are at a high risk of their RCC returning after they have undergone nephrectomy (surgical removal of the kidney affected by cancer), acting as an adjuvant therapy in these situations.

Sinton is also utilized in the management of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) that are locally advanced or have spread to other parts of the body (metastatic). The treatment is associated with disease stabilization in many individuals with these conditions.

The eligibility for Sinton is defined by regulatory bodies (e.g., FDA, EMA) based on patient population, age, and pre-existing medical conditions. It is approved exclusively for adult patients (18 years and older).

Sinton is strictly contraindicated in the following groups:

• Patients with known hypersensitivity to the active substance, sunitinib, or to any component of the formulation.
• Women who are pregnant, as Sinton can cause fetal harm.

Population Group	Eligibility Status (Regulatory Wording)
Pediatric Patients (< 18 yrs)	Safety and efficacy have not been established; use is not recommended.
Severe Hepatic Impairment (Child-Pugh Class C)	Use cannot be recommended (due to insufficient study data).
Breastfeeding Women	Not recommended (discontinuation of breastfeeding advised).

Sinton treatment must be permanently discontinued if the patient develops severe conditions such as clinical manifestations of Congestive Heart Failure (CHF) or severe dermatologic toxicities (e.g., Stevens-Johnson Syndrome).

Interactions with other medicines and products

Sinton (Naproxen Sodium) is officially documented by regulatory authorities to engage in specific interaction patterns with medicinal products and other substances, based on pharmacodynamic and pharmacokinetic effects.

Contraindicated Combinations and Restrictions

Use of Sinton is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. It is also prohibited in individuals with a history of allergic-type reactions, such as asthma or urticaria, caused by taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Co-administration with other NSAIDs is not generally recommended due to the cumulative risk of serious gastrointestinal adverse events.

Documented Drug Interactions

Pharmacodynamic Interactions (Risk of Bleeding/Ulceration): Sinton increases the risk of bleeding when co-administered with anticoagulants (e.g., Warfarin) and antiplatelet agents, including SSRIs. The risk of gastrointestinal bleeding is also heightened by concomitant use with corticosteroids.

Pharmacodynamic Interactions (Efficacy Diminution): Sinton may diminish the antihypertensive effect of medicines like ACE Inhibitors, ARBs, and Beta-Blockers, and reduce the natriuretic effect of diuretics.

Pharmacokinetic Accumulation: Sinton increases the plasma concentrations and prolongs the half-lives of lithium and digoxin. Co-administration with probenecid also leads to increased plasma levels of naproxen. The label requires Sinton not to be used for 8 to 12 days after mifepristone administration.

Substance and Population Notes

The risk of severe stomach bleeding is increased if three or more alcoholic drinks are consumed daily. Co-administration with ACE Inhibitors or ARBs may result in the deterioration of renal function in the elderly, volume-depleted, or renally impaired.

Molecular Inhibition of Prostanoid Biosynthesis

Sinton's core action involves the reversible inhibition of Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. By blocking the active site of these enzymes, the drug restricts the conversion of arachidonic acid into various prostaglandins and thromboxanes, key mediators involved in numerous physiological processes.

---

Central and Peripheral Pathway Modulation

The mechanistic effect occurs in two key areas. Peripherally, limiting prostanoid synthesis leads to reduced sensitization of nociceptive fibers and decreased production of mediators that increase vascular permeability. Centrally, this same inhibition within the hypothalamus prevents the synthesis of Prostaglandin E2 ( PGE2), which is responsible for elevating the body's thermoregulatory set point, resulting in modulation of central thermoregulation.

---

Inherent Physiological Constraints

As a non-selective inhibitor, the mechanism includes the unavoidable suppression of COX-1 activity in homeostatic systems, notably in platelets and the gastrointestinal lining. This limits the production of protective prostaglandins necessary for mucosal defense and temporarily impairs the synthesis of Thromboxane A2 ( TXA2), a crucial factor for platelet aggregation.

Sinton is approved exclusively for oral administration and is manufactured in multiple forms, including immediate-release tablets, delayed-release (EC) tablets, extended-release (ER) formulations, and an oral suspension. The foundational principle governing its use is to administer the lowest effective dosage for the shortest duration necessary to manage the patient’s condition.

The administration schedule is determined by the specific formulation used. Immediate-release and delayed-release forms are generally taken in divided doses per day for chronic conditions. In contrast, extended-release formulations are administered once daily to maintain a consistent therapeutic profile. For acute, intermittent uses, the medication may be taken every 6 to 12 hours, with the total daily dose for these forms generally not exceeding 1100 mg naproxen sodium equivalent.

Regarding intake, Sinton may be taken with food, milk, or antacids to mitigate the potential for gastrointestinal upset. A key procedural constraint is that delayed-release and extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken to maintain the intended drug release profile. Dosage adjustment is necessary for specific populations, as the medication is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/ min).

Research Evidence / Overview of Studies

Key Findings from Clinical Trials

Research has investigated the safety and tolerability profile of Sinton across multiple randomized controlled trials (RCTs) involving thousands of participants.

Studies have explored the drug's interaction with the biological processes associated with inflammation. One systematic review of 12 trials reported associations with changes in pain scores and function, particularly in individuals with moderate to severe symptoms. Another large-scale trial focused on maintenance therapy, examining effects on the frequency of flare-ups over a period of two years.

---

Specific Indications Examined in Research

For Chronic Inflammatory Disease

Research has investigated the use of Sinton in relation to chronic inflammatory disease. An 18-month, double-blind study evaluated whether the drug was associated with changes in joint stiffness over time. Data from this study indicated that the primary objective was to evaluate whether the drug was associated with the maintenance of a state of low disease activity, as measured by standardized clinical tools.

Use in Combination Therapy

Studies have also examined Sinton in combination with other treatments for individuals with specific disease types. This research primarily focused on measuring changes in disease activity and quality of life when the drug was added to an existing therapeutic regimen.

Research has also explored the drug's co-administration with other treatments in the context of adverse reactions. One Phase III trial evaluated whether the drug influenced the occurrence of common side effects when given alongside a standard therapy.

---

Important Research Considerations

Research has examined the effects of treatment interruption. In one study, participants who paused treatment reported an association with an increased potential for disease activity recurrence compared to those who maintained continuous therapy. The data gathered informs research design regarding the consistency of treatment protocols.

Common questions about Sinton (FAQ)

Q: How quickly should someone expect to feel effects from Sinton?

Sinton's active ingredient, naproxen sodium, is chemically structured as a salt form. Official regulatory documents indicate this design allows for rapid absorption into the body. This means peak levels of the medication in the blood are typically reached within 1 to 2 hours after taking the tablet or capsule.

Q: What is the longest period of time people typically use Sinton?

Official product information allows for the use of Sinton for both acute, short-term relief and long-term management of chronic conditions. While use for chronic conditions may be permitted for an extended duration, such as up to six months in some regulatory documents, the total duration depends on the specific formulation and the condition being managed.

Q: Can Sinton cause weight gain or loss?

While not listed among the commonly reported effects from clinical trials, postmarketing reports for the active ingredient do include instances of weight gain and fluid retention, sometimes called edema. This type of observation is typically noted in postmarketing reports.

Q: Can Sinton affect a person's mood?

Official reports on the medication's safety profile indicate that rare adverse reactions affecting the nervous system have been reported. Rare adverse reactions affecting the nervous system have been reported, including changes in mood, confusion, or depression.

Q: Are there any specific foods or drinks to avoid when using Sinton?

Official labeling contains a clear warning regarding alcohol consumption. The risk of severe stomach bleeding is documented to increase when the medication is combined with the daily consumption of three or more alcoholic drinks. Beyond this specific warning, Sinton is often described as being taken with food or milk to help lessen the chance of stomach upset.

Q: What is the difference between Sinton and other similar medicines I've heard about?

Sinton's active component is classified as a non-selective Nonsteroidal Anti-inflammatory Drug (NSAID) that is structurally derived from propionic acid. Regulatory documents explain that the addition of the sodium salt to the compound allows for faster absorption when compared to the base naproxen compound. This design choice results in the medication reaching peak levels more quickly.

Q: Can elderly patients use Sinton?

Yes, regulatory documents do address the use of Sinton in elderly patients. Official labeling states that older adults have a higher risk for serious side effects, especially fatal gastrointestinal (GI) events. Official guidelines note that dosage considerations, such as using the lowest effective dose, are generally applied for this population.

Q: What are the risks of using Sinton during pregnancy?

The official product information specifies that Sinton is strictly contraindicated (prohibited) after 20 weeks of pregnancy. This is due to the potential for fetal kidney problems, which can lead to low amniotic fluid. It is also prohibited during the third trimester because of the risk of causing premature closure of the fetal heart's ductus arteriosus.

Q: Can I drive or operate heavy machinery while taking Sinton?

Regulatory guidelines contain a patient warning that activities requiring alertness, such as driving or operating machinery, should be avoided if side effects like dizziness, drowsiness, or visual disturbances occur. This information is included in patient counseling sections of the official label.

Q: Does Sinton affect sleep patterns?

The adverse reaction listings for the active ingredient include reports of both drowsiness and insomnia (difficulty sleeping). These effects are documented in clinical trial data and postmarketing experience, meaning the medication may either promote sleepiness or interfere with sleep.

Q: How long does Sinton stay in the body after the last dose?

The amount of time the active ingredient remains in the body is documented in the pharmacokinetic section of the official label. The drug is eliminated relatively slowly, with its elimination half-life typically ranging from 12 to 17 hours.

Q: Is there a generic version of Sinton available?

Sinton is a brand name for the active ingredient Naproxen Sodium. Official listings from regulatory bodies confirm that the compound Naproxen Sodium is available in many general-purpose, generic formulations that have been approved for use.

Q: Is Sinton safe for patients with high blood pressure?

Official labeling contains warnings about this potential issue. Studies indicate that Sinton can lead to new or worsening hypertension (high blood pressure). Additionally, the medication may lessen the effectiveness of certain blood pressure medications. Regulatory documents recommend that blood pressure be monitored during the initiation and course of NSAID therapy.

Q: Do patients typically need a follow-up appointment soon after starting Sinton?

Regulatory documents recommend that blood pressure be monitored during the initiation of NSAID treatment and throughout the course of therapy. Official guidelines also note that certain high-risk patient populations may require monitoring of liver and kidney function.

How to Store and Dispose of Sinton?

Sinton (Naproxen Sodium) must be stored strictly according to regulatory mandates to ensure stability and integrity. The product requires storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C.

The container must be kept tightly closed in a dry place and protected from light and excessive heat, as the medicine is sensitive to moisture. It is a mandatory requirement to keep Sinton out of the sight and reach of children.

For disposal, do not flush Sinton down the toilet or discard it in household trash. Unused or expired medication must be handled according to local pharmaceutical waste regulations, often utilizing medicine take-back programs.